Printer Friendly
The Free Library
23,389,518 articles and books


Agencourt Launches Premier Research Sample Sequencing Service; The First Fully Automated High Performance Sequencing Pipeline for Individual Sequencing Samples.

Business Editors/Health/Medical Writers

BEVERLY, Mass.--(BUSINESS WIRE)--Sept. 22, 2003

Agencourt Bioscience Corporation, a provider of genomic services and nucleic acid purification products to the life sciences industry, today introduced QuickLane(TM) Research Sample Sequencing, a new sequencing service for individual research samples. Researchers can now submit a single sample for sequencing using Agencourt's high performance genomic pipeline and receive results within 24 to 48 hours.

Agencourt is well respected for quality sequencing in a high throughput environment, having an established genomics pipeline with the capacity to sequence over 20 million Phred20 bases per day. This pipeline is now available to customers with individual research samples through Agencourt's QuickLane Research Sample Sequencing service.

Distinguishing features of Agencourt's QuickLane sequencing service are the fully automated sample handling and the high level of data tracking involved from the time of sample submission in 2D bar coded tubes to data delivery via a secure FTP site.

"We understand that every sample is important to our clients, so sample tracking and data management are a top priority at Agencourt," says Brendan McKernan, Vice President, Manufacturing and Operations, Agencourt Bioscience. "Customers submit samples to us in 2D bar coded tubes which are directly integrated into our Galaxy LIMS (Laboratory Information Management System) for complete and uncompromised tracking. With the introduction of Agencourt's QuickLane Research Sample Sequencing service, researchers can not only quickly receive high quality sequence data, but also have complete confidence in the integrity of their data."

About Agencourt Bioscience Corporation

Agencourt Bioscience Corporation is a provider of genomic services and nucleic acid purification products that help biotech and pharmaceutical companies improve the effectiveness and efficiency of their drug development pipelines. Agencourt's Discovery Solutions(TM) suite of genomic and functional genomic services include high-throughput sequencing, SAGE(TM) sequencing, SNP discovery and genotyping. The company's purification products and services are based on the proven and patented Solid Phase Reversible Immobilization (SPRI) technology, which has been adopted by several of the largest genome research facilities, resulting in more base pairs contributed to GenBank than any other nucleic acid purification technology and used to sequence over one-third of the human genome. Several of Agencourt's founders worked at the Whitehead Institute Center for Genome Research, and have significant experience in combining the chemistries and instrumentation for high-throughput genomics. Agencourt is located in Beverly, Massachusetts and is available on the Web at www.agencourt.com.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 22, 2003
Words:398
Previous Article:BigBand Networks and Internet Photonics Team to Provide Video Transport Solutions for Cable Operators.
Next Article:Aphton to Present At the UBS Global Life Sciences Conference.



Related Articles
Forensic mitochondrial DNA analysis: A different crime-solving tool.
Research-grade rheometer is fast & flexible. (Keeping Up With Auxiliaries).
Rabies in Sri Lanka: splendid isolation. (Dispatches).
Global screening for human viral pathogens. (Perspectives).
454 LIFE SCIENCES GETS GENOME LICENSE FROM PYROSEQUENCING.
Quantitative PCR deconstruction of discrepancies between results reported by different hybridization platforms.
Revolutionary genome sequencing technologies--the $1,000 genome.
Near-term technology development for genome sequencing.
Detecting biological warfare agents.
Molecular characterization of tickborne relapsing fever Borrelia, Israel.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters